|
Original version Date: 4/12/2018
|
| bet | 509/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Original version Date: 4/12/2018
|
Author: NMF Consensus Group
|
Current Version number: 1
|
Current Version Date: 13/12/2018
|
Risk Rating: Low
|
Due for Review: 13/12/2023
|
Approval by: DTC
|
Approval Date:
|
Propranolol |
Revision Date : 15-4-2019
|
Approved: TC, KOH
|
Alert
|
For dosing on infantile haemangiomas – please refer to “Propranolol for Infantile Haemangioma” formulary.
For infants with comorbidities that are likely to lead to hypoglycaemia (e.g.
hyperinsulinism/preterm/low weight) – dose schedule needs to be cautious.
Ensure infant has adequate enteral or parenteral nutrient intake.
|
Indication
|
Supraventricular and ventricular tachycardia
Prevention of hypercyanotic episodes in unrepaired Tetralogy of Fallot
Hypertrophic cardiomyopathy
Systemic hypertension
Thyrotoxicosis – treatment of sympathetic overactivity
Phaeochromocytoma (with an alpha-blocker)
Retinopathy of prematurity (not recommended)
Infantile haemangioma – Please refer to “Propranolol for Infantile Haemangioma”
formulary.
|
Action
|
Beta-blockers competitively block beta-adrenoceptors in heart, peripheral vasculature, bronchi, pancreas, uterus, kidney, brain and liver. Beta-blockers reduce heart rate, blood pressure (BP) and cardiac contractility; also depress sinus node rate and slow conduction through the atrioventricular (AV) node and prolong atrial refractory periods.
|
Drug Type
|
Beta-adrenergic blocker
|
Trade Name
|
Deralin, Inderal tablets, Hemangiol, Propranolol Auspman
|
Presentation
|
Deralin, Inderal, tablet 10 mg, 40 mg,
Deralin tablet 160 mg
Propranolol (Auspman) 2 mg/mL Oral Solution
Hemangiol 3.75 mg/mL Oral Solution
Propranolol suspension (formulas for multiple concentrations exist) compounded by
Pharmacy Department
|
|
|
| |
